TACS Consumer Health
A disruptive, consumer healthcare provider of direct subscription access to prescription strength drugs without required MD oversight
NJ early stage company with a $10-25B target annual market. TACS Consumer Healthcare can capture a majority of sales through successive pipeline launches using a patent-pending model enabling Rx to Non-Rx switches of drugs not normally able to be regulated as Over the Counter. Yr 1 National US target of $200MM with sales growing to $825MM by Yr 5 for the first drug only. Cumulative projected 10-year EBITDA of $500MM.